COMPLETEDN/A

Breast Study to Learn More About the Application of Optical Transillumination Measurements to Assess Breast Cancer Risk and to Potentially Detect the Presence of Breast Cancer.

This study aims to evaluate if a light based technique, called Transillumination Breast Spectroscopy (TIBS), can be used to construct a non-invasive breast cancer risk predictor which provides a better odds ratio than mammographic parenchymal density.

Sponsor

University Health Network, Toronto

Enrollment

500 participants

Sites

2 locations

Start Date

July 2006

Completion

March 2009

Breast Cancer

Enrollment & Timeline

Completed

Target enrollment (estimated)

Target N

500

participants

Sites

locations

Duration

3.2 years

total trial span

Rate

pts/month needed

At 2 sites, each site needs to enroll approximately 6.5 patients/month to hit the enrollment target on schedule.

Enrollment target is estimated. ClinicalTrials.gov does not provide real-time enrollment progress.

View on ClinicalTrials.gov

Ask AI

Eligibility

Min Age

30 Years

Max Age

Ask AI

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

Non-ionizing near-infrared radiation transillumination spectroscopy for breast tissue density and assessment of breast cancer risk.

Simick Michelle K, Jong Roberta, Wilson Brian et al.Journal of biomedical optics2005

DOI PubMed

Classification of breast tissue density by optical transillumination spectroscopy: optical and physiological effects governing predictive value.

Blyschak Kristina, Simick Michelle, Jong Roberta et al.Medical physics2005

DOI PubMed

Optical transillumination spectroscopy to quantify parenchymal tissue density: an indicator for breast cancer risk.

Simick M K, Lilge LThe British journal of radiology2005

DOI PubMed

Assessing breast tissue density by transillumination breast spectroscopy (TIBS): an intermediate indicator of cancer risk.

Blackmore K M, Knight J A, Jong R et al.The British journal of radiology2007

DOI PubMed

PubMed/NCBI (daily updates) FDA FAERS (quarterly updates) WHO ICTRP (weekly updates)

Ask AI

Fetching protocol from ClinicalTrials.gov…

COMPLETEDN/A

Breast Study to Learn More About the Application of Optical Transillumination Measurements to Assess Breast Cancer Risk and to Potentially Detect the Presence of Breast Cancer.

Sponsor

University Health Network, Toronto

Enrollment

500 participants

Sites

2 locations

Start Date

July 2006

Completion

March 2009

Breast Cancer

Enrollment & Timeline

Completed

Target enrollment (estimated)

Target N

500

participants

Sites

locations

Duration

3.2 years

total trial span

Rate

pts/month needed

At 2 sites, each site needs to enroll approximately 6.5 patients/month to hit the enrollment target on schedule.

Enrollment target is estimated. ClinicalTrials.gov does not provide real-time enrollment progress.

View on ClinicalTrials.gov

Ask AI

Eligibility

Min Age

30 Years

Max Age

Ask AI

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

Non-ionizing near-infrared radiation transillumination spectroscopy for breast tissue density and assessment of breast cancer risk.

Simick Michelle K, Jong Roberta, Wilson Brian et al.Journal of biomedical optics2005

DOI PubMed

Classification of breast tissue density by optical transillumination spectroscopy: optical and physiological effects governing predictive value.

Blyschak Kristina, Simick Michelle, Jong Roberta et al.Medical physics2005

DOI PubMed

Optical transillumination spectroscopy to quantify parenchymal tissue density: an indicator for breast cancer risk.

Simick M K, Lilge LThe British journal of radiology2005

DOI PubMed

Assessing breast tissue density by transillumination breast spectroscopy (TIBS): an intermediate indicator of cancer risk.

Blackmore K M, Knight J A, Jong R et al.The British journal of radiology2007

DOI PubMed

PubMed/NCBI (daily updates) FDA FAERS (quarterly updates) WHO ICTRP (weekly updates)

Ask AI

View full criteria

Inclusion Criteria:

* Are in good health and capable of providing consent
* Are willing to come in to the Princess Margaret Hospital for a single visit to meet with a female research assistant

Exclusion Criteria:

* Have had breast augmentation or reduction
* Have a personal history of breast cancer
* Have had a previous bilateral fine needle aspiration or core biopsy
* Have a breast tattoo

Breast Study to Learn More About the Application of Optical Transillumination Measurements to Assess Breast Cancer Risk and to Potentially Detect the Presence of Breast Cancer.

Enrollment & Timeline

Eligibility

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

Breast Study to Learn More About the Application of Optical Transillumination Measurements to Assess Breast Cancer Risk and to Potentially Detect the Presence of Breast Cancer.

Enrollment & Timeline

Eligibility

Multi-Source Intelligencefrom PubMed · FDA FAERS · WHO ICTRP

Trial Sites (2)